https://pubmed.ncbi.nlm.nih.gov/38114231
The abstract describes a successful feasibility study of a personalized autologous T-cell therapy (IMA101) for advanced cancer patients, which was found to be safe, well-tolerated, and showed early signs of efficacy, justifying further investigation.